SCYX News and Press, SCYNEXIS Inc. From 09/08/22

Approximately 83% of FURI patients with refractory Candida infections had positive clinical outcomes, defined as complete/partial response (56%) or no disease progression (27%). Data from the ongoing Phase 3 CARES study will also be presented demonstrating positive outcomes of...

JERSEY CITY, N.J., Sept. 01, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced it will present posters at four upcoming U.S. and inter...

Summary SCYX has a commercial antifungal Brexafemme. However, we are neutral on its commercial potential as discussed in our previous article. No big pharma deal materialized, and the company raised USD45M through pre-funded warrant offerings. The drug's true upside is in syst...

SCYNEXIS, Inc. (SCYX) Q2 2022 Results Conference Call August 15, 2022 08:30 AM ET Company Participants Debbie Etchison - Communications and IR Dr. Marco Taglietti - President and CEO Christine Coyne - Chief Commercial Officer Dr. David Angulo - Chief Medical ...

Scynexis ( NASDAQ: SCYX ) stock rose ~3% on Aug. 15 after Q2 revenue grew 29% Q/Q. Sales of vaginal yeast infection drug Brexafemme (ibrexafungerp tablets) increased to $1.3M in Q2, compared to $0.7M in Q1. "We are pleased to see the improvements to th...

SCYNEXIS press release ( NASDAQ: SCYX ): Q2 GAAP EPS of -$0.31 beats by $0.28 . Revenue of $1.32M misses by $0.32M . Cash and cash equivalents totaled $118.7 million on June 30, 2022, compared to $104.5 million in cash and cash equivalents on December 31, 2021....

BREXAFEMME ® (ibrexafungerp tablets) prescriptions in Q2 2022 increased 29 percent over Q1 2022, generating net revenues of $1.3 million in Q2 2022, compared to $0.7 million in Q1. SCYNEXIS filed a supplemental New Drug Application (sNDA) to expand BREXAFEMME’s lab...

SCYNEXIS ( NASDAQ: SCYX ) is scheduled to announce Q2 earnings results on Monday, August 15th, before market open. The consensus EPS Estimate is -$0.59 (-168.2% Y/Y) and the consensus Revenue Estimate is $1.64M Over the last 3 months, EPS estimates have seen 2 upward...

JERSEY CITY, N.J., Aug. 09, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced it will host a conference call and live webcast at 8:30 ...

The CANDLE study met its primary endpoint, with 65.4% of patients with recurrent vulvovaginal candidiasis (RVCC) who received monthly single-day ibrexafungerp treatment achieving clinical success with no recurrence at all, either culture-proven, presumed or suspected. Ibrexafunger...